NICOX SA (COX.PA) Stock Price & Overview
EPA:COX • FR0013018124
Current stock price
The current stock price of COX.PA is 0.579 EUR. Today COX.PA is down by -0.52%. In the past month the price decreased by -8.1%. In the past year, price decreased by -66.14%.
COX.PA Key Statistics
- Market Cap
- 28.918M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.61
- Dividend Yield
- N/A
COX.PA Stock Performance
COX.PA Stock Chart
COX.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to COX.PA. When comparing the yearly performance of all stocks, COX.PA is a bad performer in the overall market: 98.25% of all stocks are doing better.
COX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COX.PA. COX.PA may be in some trouble as it scores bad on both profitability and health.
COX.PA Earnings
COX.PA Forecast & Estimates
8 analysts have analysed COX.PA and the average price target is 2.91 EUR. This implies a price increase of 402.07% is expected in the next year compared to the current price of 0.579.
For the next year, analysts expect an EPS growth of 35.92% and a revenue growth 16.23% for COX.PA
COX.PA Groups
Sector & Classification
COX.PA Financial Highlights
Over the last trailing twelve months COX.PA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 47.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.47 |
COX.PA Ownership
COX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 29.22 | 42.202B | ||
| 1AE | ARGENX SE | 29.42 | 42.19B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.117B | ||
| ABVX | ABIVAX SA | N/A | 8.555B | ||
| 2X1 | ABIVAX SA | N/A | 8.555B | ||
| GLPG | GALAPAGOS NV | N/A | 1.608B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| NANO | NANOBIOTIX | N/A | 1.238B | ||
| PHARM | PHARMING GROUP NV | 48.09 | 1.036B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.007B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 975.338M | ||
| PHGN | PHARMING GROUP NV | 45.96 | 975.297M | ||
| IVA | INVENTIVA SA | N/A | 939.888M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About COX.PA
Company Profile
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Company Info
IPO: 1999-11-02
NICOX SA
Drakkar 2 - Batiment D, 2405 route des Dolines, CS 10313 Sophia Antipolis
Valbonne PACA FR
Employees: 32
Phone: 33497245300.0
NICOX SA / COX.PA FAQ
What does NICOX SA do?
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
What is the stock price of NICOX SA today?
The current stock price of COX.PA is 0.579 EUR. The price decreased by -0.52% in the last trading session.
What is the dividend status of NICOX SA?
COX.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of COX stock?
COX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for NICOX SA?
NICOX SA (COX.PA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for NICOX SA?
The Revenue of NICOX SA (COX.PA) is expected to grow by 16.23% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of COX stock?
NICOX SA (COX.PA) has a market capitalization of 28.92M EUR. This makes COX.PA a Nano Cap stock.